Focused On-demand Library for Jouberin

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

Abelson helper integration site 1 protein homolog

Alternative UPACC:

Q8N157; E1P584; Q4FD35; Q504T3; Q5TCP9; Q6P098; Q6PIT6; Q8NDX0; Q9H0H2


Jouberin, also known as Abelson helper integration site 1 protein homolog, plays a pivotal role in vesicle trafficking, ciliogenesis, and neuronal differentiation. It is a crucial component of the tectonic-like complex, essential for maintaining the integrity of primary cilia and facilitating ciliary signaling, particularly during cerebellum embryonic development. Its involvement in classical Wnt signaling underscores its significance in cellular communication and development.

Therapeutic significance:

Jouberin's association with Joubert syndrome 3, characterized by cerebellar ataxia, oculomotor apraxia, and potential renal disease, highlights its therapeutic significance. Understanding the role of Jouberin could open doors to potential therapeutic strategies for treating or managing this complex disorder, emphasizing the need for targeted research into its functions and disease mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.